As the cannabis industry continues to grow, more companies are expanding their product lines beyond traditional flower sales. This includes edibles, oils, and wellness products, attracting a broader consumer base. The demand for more cannabis products is helping bridge some gaps between existing players. For example, when companies partner in some way to create and release products, it often has a positive impact all the way around for the companies.
The mean of analysts' price targets for Aurora Cannabis (ACB) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BHRB, ACB, MWA, BJ and PRTH have been added to the Zacks Rank #1 (Strong Buy) List on February 21, 2024.
ACB, and PRTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 21, 2024.
Aurora Cannabis (ACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The patience of some marijuana stock investors is still being tested. The public sector for cannabis is a victim of uncertainty and fear in more grey areas. What this means is in the USA there is no federal reform that protects legal operators in any way. Yet states have independently voted to legalize cannabis. From this legal markets are created and legal companies can now produce a federally illegal product.
NASDAQ | TSX: ACB The collaboration aims to broaden access of premium medical cannabis products to Australian patients EDMONTON, AB , Dec. 17, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce a distribution partnership between The Entourage Effect and MedReleaf Australia. The Entourage Effect provides comprehensive distribution and support services to pharmacies in Australia and will serve as a wholesaler for MedReleaf Australia's leading portfolio of products under the CraftPlant, Aurora, and IndiMed brands, furthering the mission to expand access for Australian patients.
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.50 per share a year ago.
Aurora Cannabis Inc. (NASDAQ:ACB ) Q2 2025 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Kevin Niland - Director, Strategic Finance and IR Miguel Martin - CEO Simona King - CFO Conference Call Participants Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Operator Greetings and welcome to the Aurora Cannabis Inc. Second Quarter 2025 Results Conference Call. all participants will be in a listen-only mode and a question-and-answer session will follow the formal presentation.
NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB , Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director.